Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, we aimed to investigate promoter methylation of three tumor-suppressor genes (BRCA-1, MGMT, and P16) and three histone marks (H3K9ac, H3K18ac, and H4K20me3) in patients with breast tumors.
|
30938887 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here we present a systematic genomic analysis of breast tumors with BRCA1 and BRCA2 mutations.
|
31182087 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tissues obtained from healthy women who breastfed for < 6 months vs ≥ 6 months showed significant enrichment of Notch signaling pathway genes, along with a trend for enrichment for luminal progenitor gene signature similar to what is observed in BRCA1 mutation carriers and basal-like breast tumors.
|
31315645 |
2019 |
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Of the 141 breast tumors, 45 samples (32%) had high HRD scores and were associated with high histological grade (P = 0.001), negative progesterone receptor (P = 0.018), high Ki67 index (P = 0.032), and BRCA1 promoter methylation (P = 3.6e-07).
|
30607631 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Homologous recombination deficiency conferred by alterations in BRCA1 or BRCA2 are common in breast tumors and can drive sensitivity to platinum chemotherapy and PARP inhibitors.
|
31499327 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In this review, we use the Microcompetition Model to explain how certain latent viruses, which are frequently detected in breast cancer tumors, can decrease the expression of the BRCA1 gene and cause the development of breast tumors.
|
30579323 |
2019 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
These cumulative data support the hypothesis that exposure to AsIII may contribute to reducing the efficacy of endocrine therapy against ERα‑positive breast tumors by hampering the expression of ERα and BRCA1 via CpG methylation, respectively of ESR1 and BRCA1.
|
30664189 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Targeting the β-hCG-HSP90-TGFBRII axis could prove an effective treatment strategy for BRCA1-mutated breast tumors.
|
30963174 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We studied the breast tumor profile associated to the c.3481_3491del11 French founder effect mutation on the BRCA1 gene to an attempt to identify any particularity or difference when comparing it to that related to other BRCA1 mutations.
|
29550896 |
2019 |
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
We retrained and validated a copy-number-based support vector machine (SVM) classifier to identify HR-deficient, BRCA1-like breast tumors.
|
30683142 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Although ATM is involved in the DNA damage response, ATM-associated tumours are distinct from BRCA1-associated tumours in terms of morphological characteristics and genomic alterations, and they are also distinguishable from sporadic breast tumours, thus opening up the possibility to identify ATM variant carriers outside the ataxia-telangiectasia disorder and direct them towards effective cancer risk management and therapeutic strategies.
|
29665859 |
2018 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Hormonal replacement experiments in ovariectomized mice showed that BRCA1-deficient mammary tumor formation is promoted by estrogen but not by progesterone.
|
29877575 |
2018 |
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Corresponding tumour-derived DNA available from 5 of these 7 women had elevated methylation within the BRCA1 and SPHK2 promoter region and decreased methylation within the ADAP1, IGF2BP3 and SPATA13 promoter region when compared with the other breast tumours.
|
30423315 |
2018 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We identified 140 differentially expressed miRNAs, 9 of which were also differentially expressed in human BRCA1 breast tumours or familial non-BRCA1 patients and during normal gland development.
|
30323900 |
2018 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Breast tumors deficient in BRCA1 are mostly associated with basal-like breast cancers and targeted therapeutics for this disease subtype are still lacking.
|
29938573 |
2018 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In this paper, we focus our interest on the dynamics alterations of the tumor-stroma interface at the ultrastructural level and to detect BRCA1 and BRCA2 mutations using next generation sequencing (NGS) of breast tumor tissue.
|
28730229 |
2017 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The increased propensity of BRCA1 mutation carriers to develop aggressive breast tumors with stem-like properties begins to be understood in terms of osteoprotegerin (OPG)-unrestricted cross-talk between RANKL-overproducing progesterone-sensor cells and cancer-initiating RANK<sup>+</sup> responder cells that reside within pre-malignant BRCA1<sup>mut/+</sup> breast epithelial tissue.
|
28387573 |
2017 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Retention of the normal BRCA1 or BRCA2 allele (absence of locus-specific loss of heterozygosity (LOH)) is observed in 7% of BRCA1 ovarian, 16% of BRCA2 ovarian, 10% of BRCA1 breast, and 46% of BRCA2 breast tumors.
|
28831036 |
2017 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Overall, our findings highlight a critical role of Rak in the maintenance of genomic stability, at least in part, through protecting BRCA1 and provide novel treatment strategies for patients with breast tumors lacking Rak.
|
29156836 |
2017 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Using genetic mouse-models, we and others identified the RANKL/RANK system as a key regulator of sex hormone, BRCA1-mutation, and oncogene-driven breast cancer and we proposed that RANKL/RANK might be involved in the initiation of breast tumors.
|
28002811 |
2017 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The fate of BRCA1-related germline mutations in triple-negative breast tumors.
|
28123851 |
2017 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
|
28825726 |
2017 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Most BRCA1-associated breast tumours are basal-like yet originate from luminal progenitors.
|
28649985 |
2017 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In conclusion, proteome profiling of secretome using murine breast tumor models is a powerful strategy to identify non-invasive candidate biomarkers of BRCA1-deficient breast cancer.
|
27566577 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
|
27257965 |
2016 |